Epygenix Therapeutics

We are a clinical stage precision medicine-based biopharmaceutical company developing drugs for rare and intractable forms of genetic epilepsy.

We are the leader in the rare genetic epilepsy space with the diversified drug pipeline.

We will be the first biopharmaceutical company to launch novel epilepsy drugs discovered in zebrafish-based screening system.

Epygenix Therapeutics is a clinical stage biopharmaceutical company developing the precision medicine for rare and refractory genetic epilepsy, such as Dravet syndrome and Lennox-Gastaut syndrome.

Clipboard

Clinical Trial

Epygenix zebrafish-to-man translation strategy expedited the further investigation of EPX-100, -200, and -300 in Dravet syndrome patients.

Gene

Therapeutic Focus

Epygenix Therapeutics focuses on development of new treatments for rare and catastrophic forms of genetic epilepsy, including Dravet Syndrome, Lennox-Gastaut Syndrome, Infantile Spasm, Cute Syndrome, and Ohtahara Syndrome.

Zebrafish

Technology

Our technology rapidly identifies antiepileptic drugs and monitors toxicology – Epygenix Therapeutics used an innovative zebrafish-based platform applying phenotype-based in vivo screening.

What is Epygenix?

Epygenix Therapeutics is a clinical stage biopharmaceutical company developing drugs to treat Dravet syndrome (DS) and other genetic epilepsies. DS is a rare and catastrophic form of intractable epilepsy that begins in infancy. Current therapeutic options are not sufficient, and the constant care required can severely impact the quality of life for the entire family.

Recent News and Press Releases

Aug 02, 2021

Health Canada Grants No Objection Letter to Epygenix Therapeutics to Proceed With ARGUS Trial for the Treatment of Dravet Syndrome

Epygenix Therapeutics Receives Orphan Medicinal Product Designation in Europe With EPX-200 for the Treatment of Patients With Dravet Syndrome

Epygenix Therapeutics Receives U.S. FDA Orphan Drug Designation for EPX-200 in Lennox-Gastaut Syndrome

May 25, 2021

Epygenix: Fishing for best in class in epilepsy

May 03, 2021

Journey from Aquarium-to-Bedside to Treat Genetic Epilepsies

Nov 12, 2020

Epygenix Therapeutics Announces First Patient Successfully Dosed in Phase 2 Study for the Treatment of Dravet Syndrome With EPX-100

Oct 02, 2020

Epygenix Therapeutics Announces First Patient Enrolled in Phase 2 Study for the Treatment of Dravet Syndrome With EPX-100

Sep 17, 2020

Epygenix Therapeutics Initiates Phase 2 Study for Dravet Syndrome With EPX-100

Sep 16, 2020

EpyGenix Launches Phase II Trial for EPX-100

Jan 27, 2020

Epygenix Therapeutics Successfully Completes EPX-100 Phase I, Placebo-Controlled, Double-Blind, 2-Period Study and Ready to Phase 2 Studies

Jul 29, 2019

Epygenix Therapeutics Receives IND Approval of EPX-100 for the Treatment of Dravet Syndrome

Jun 24, 2019

Epygenix Therapeutics Submits Investigational New Drug Application for EPX-100 to the U.S. FDA for the Treatment of Patients With Dravet Syndrome

Jun 26, 2017

A New School of Drug Discovery

Jun 08, 2017

Profile of Epygenix Therapeutics is listed in June 2017 issue of Biopharma Dealmakers – Published in Nature Reviews Drug Discovery & Nature Biotechnology

Apr 25, 2017

Epygenix Therapeutics Receives Orphan Drug Designation From the U.S. FDA for EPX-100 and EPX-200 in the Treatment of Patients With Dravet Syndrome

Apr 21, 2017

“Discovering & Developing Drugs for Genetic Epilepsies” highlighted in the April 2017 issue of GHP (UK Pharma Journal)

Apr 18, 2017

Researchers Say Fish Larvae is Helping Children With Epilepsy

Feb 10, 2017

Epilepsy drug discovered in fish model shows promise in small pediatric clinical trial

Jan 18, 2017

Through the Looking Glass: The Quest by Parents and Scientists to End Pediatric Epilepsy

Jan 17, 2017

Researchers discover potential epilepsy drug using zebrafish

Potential Drug Discovered for Severe Form of Epilepsy

Zebrafish in the swim as research animals

To Learn More